Press Release

Ref: Syn/CS/SE/PR/2026-27/Jul/15 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 9191 CIN: L85110KA1993PLC014937 www.syngeneintl.com July 29, 2026 To, To, The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Corporate Communication Department Dalal Street, Mumbai – 400 001 Bandra (EAST), Mumbai – 400 051 Scrip Code: 539268 Scrip Symbol: SYNGENE Dear Sir/Madam, Sub: Press Release in respect of financial results for the quarter ended June 30, 2026. With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled “Q1 FY27 revenue from operations at Rs. 736 Cr; Operating EBITDA at Rs. 91 Cr” The above-mentioned press release will also be available on the website of the Company www.syngeneintl.com. This is for your information and records. Thanking You, Yours faithfully, For SYNGENE INTERNATIONAL LIMITED Chethan Yogesh Company Secretary and Compliance Officer Enclosed: Press Release along with fact sheet PRESS RELEASE Q1 FY27 revenue from operations at Rs. 736 Cr; Operating EBITDA at Rs. 91 Cr Bengaluru, July 29, 2026: Syngene International Limited today announced results for the first quarter of FY27. Quarterly Financial Highlights (All numbers are in Indian Rupees in Crore (Cr)) Q1 FY27 Q1 FY26 YoY Change (%) Revenue from Operations 736 875 -16% Operating EBITDA 91 206 -56% Operating EBITDA margin (%) 12% 24% PAT before exceptional item 11 87 -99% PAT Margin (%) before exceptional item 0% 10% PAT after exceptional item (9) 87 -110% 1Excludes expenses of Rs 10 Cr (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy. Syngene International Limited Executive Chairperson, Kiran Mazumdar-Shaw, said, “I have accepted to take on the role of Executive Chairperson of Syngene as we reshape the Company’s next phase of growth. Syngene has built an outstanding reputation over more than three decades, underpinned by scientific excellence, customer trust, and a culture of innovation. I look forward to working with Siddharth and his leadership team as we reposition the Company for sustainable growth, driven primarily by CDMO and AI-led advanced services. The Board has every confidence in the management’s ability to execute with focus and discipline, while continuing to create value for all stakeholders.” In his first statement as Managing Director and CEO, Siddharth Mittal said, “As I take charge of Syngene, amid headwinds that the Company is currently navigating, I look forward to working closely with the Board and our leadership team to sharpen our focus and translate our priorities into tangible business outcomes that will provide a strong foundation for long-term growth. My immediate priorities are to sharpen our commercial execution, strengthen delivery across our businesses, and build a more agile, cost-competitive organization. At the same time, we will continue to invest in CDMO, AI, innovation and differentiated scientific capabilities that will strengthen our competitive position.” Deepak Jain, Chief Financial Officer, Syngene International Limited, said, “Our performance during the quarter was primarily impacted by the lack of offtake from a major biologics client and forex hedge loss, partially offset by our ongoing cost optimization initiatives. Consequently, the operating EBITDA margin came in at 12%. We continue to maintain a strong balance sheet and financial discipline, which provides the flexibility to invest in our strategic priorities, including infrastructure, technology platforms, automation, and emerging modalities. While we expect a degrowth in the first half of the fiscal year, business momentum is expected to improve in the second half, resulting in single-digit revenue degrowth in rupee terms for the full year and EBITDA margins in the mid-20s.” Board Updates: § Dr. Kush Parmar to step down as Independent Director. Dr. Parmar has served on the Board since 2021 and was a member of the Risk Management Committee and the Science and Technology Committee. The Company places on record its appreciation for Dr. Parmar's valuable service and contributions. § Dr. Vijaya Chandru appointed as an Independent Director. An academic entrepreneur with over 25 years of leadership in deep-tech innovation, Dr. Chandru holds a Ph.D. in Operations Research from MIT. His expertise spans AI, computational biology, genomics, and CRISPR-based biotechnology. He is globally recognized for his contributions to computer science and life sciences. § Dr. Arun Chandavarkar appointed as an Independent Director. Prior to his retirement in 2019, Dr. Chandavarkar served as CEO and Joint MD of Biocon Limited. He played a key role in transforming the company into a leading global biopharmaceutical organization. He contributed to Biocon's IPO, biologics partnerships, R&D expansion, and the divestment of the enzymes business. Dr. Chandavarkar currently serves on the boards of Biocon Biologics and Mynvax. He holds a B.Tech. from IIT Bombay and a Ph.D. from MIT. Key Business Highlights: § Syngene signed a Memorandum of Understanding (MoU) with BRIC-Translational Health Science and Technology Institute (THSTI), an institute under the Biotechnology Research & Innovation Council (BRIC), Department of Biotechnology, Ministry of Science and Technology, Government of India. The collaboration establishes an operational partnership for early and late-phase clinical development, translational research, and bioanalytical sciences. The collaboration will also enable the evaluation and execution of First-in-Human (FIH) and Phase I clinical programs, along with bioanalytical, biomarker and patient-based clinical research programs. § Syngene further strengthened Syn.AI, its AI-enabled scientific platform for accelerating drug discovery services. During the quarter, the Company developed gigascale virtual screening capabilities, enabling larger libraries of molecules to be screened and prioritized, accelerating the identification of promising drug candidates. Syngene also advanced its AI-driven de novo (new molecule) design capabilities, enabling faster design and optimization of novel drug candidates. § Syngene featured in TIME Magazine and Statista's "World's Most Sustainable Companies 2026" ranking for the second consecutive year. Selected from more than 5,800 companies across 43 countries, Syngene ranked among the world's top 750 most sustainable companies, reinforcing its position as one of the leading pharmaceutical and biotechnology companies globally. Earnings Call: Syngene will host an investor call at 9 am IST on July 30, 2026, where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1279 / +91 22 7115 8180. Participants can also join the call via this webcast link. Other toll numbers are listed in the conference call invitation, which is posted on the Company website www.syngeneintl.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available until August 05, 2026, on 91 22 71945757, Playback ID: 48209#. We will aim to post the transcript of the conference call on the company website within seven working days of the investor conference call. About Syngene: Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors [Showing first 8,000 characters — download PDF for full document]